

CONSOLIDATED						Sr. No.	Particulars	COMPANY					
Rupees in Lacs [except for share data]								Rupees in Lacs [except for share data]					
3 Months Period ended on December 31, 2011 [Unaudited]	3 Months Period ended on September 30, 2011 [Unaudited]	Corresponding 3 Months Period ended on December 31, 2010 [Unaudited]	9 Months Period ended on December 31, 2011 [Unaudited]	Corresponding 9 Months Period ended on December 31, 2010 [Unaudited]	Previous accounting Year ended on March 31, 2011 [Audited]			3 Months Period ended on December 31, 2011 [Unaudited]	3 Months Period ended on September 30, 2011 [Unaudited]	Corresponding 3 Months Period ended on December 31, 2010 [Unaudited]	9 Months Period ended on December 31, 2011 [Unaudited]	Corresponding 9 Months Period ended on December 31, 2010 [Unaudited]	Previous accounting Year ended on March 31, 2011 [Audited]
137,364	123,887	114,713	380,141	333,667	452,111	1	Sales & Income from operations :						
2,118	1,923	1,258	5,580	4,071	5,644	A	Gross Sales	66,434	60,991	55,047	185,091	169,676	221,129
135,246	121,964	113,455	374,561	329,596	446,467	B	Less : Excise Duty	1,148	929	834	3,052	2,537	3,506
3,076	1,676	3,226	11,970	12,132	16,552	C	Net Sales	65,286	60,062	54,213	182,039	167,139	217,623
138,322	123,640	116,681	386,531	341,728	463,019	D	Other Income from Operations	16,176	16,989	15,980	54,661	55,294	74,365
						E	Total sales and other income from operations	81,462	77,051	70,193	236,700	222,433	291,988
(8,728)	(5,660)	(1,207)	(20,695)	(4,858)	599	2	Expenditure :						
24,901	33,037	22,347	84,419	73,037	100,711	A	Increase [-] / Decrease [+] in stock in trade & works in progress	(2,557)	(2,309)	(580)	(5,880)	(3,810)	(3,506)
29,028	11,678	14,576	56,735	35,545	46,228	B	Consumption of materials	18,082	20,070	13,855	56,562	48,152	67,670
19,215	18,029	14,458	53,391	41,376	60,892	C	Purchase of traded goods	11,198	7,890	5,313	25,229	17,672	22,830
4,654	3,754	3,335	11,880	9,518	12,692	D	Employees cost	10,412	10,294	8,512	30,699	25,509	38,724
47,747	42,849	40,890	132,576	116,791	151,970	E	Depreciation, Amortisation & Impairment	2,686	2,754	2,465	7,937	7,218	9,685
116,817	103,687	94,399	318,306	271,409	373,092	F	Other Expenditure	30,681	25,180	26,317	81,476	74,221	95,499
21,505	19,953	22,282	68,225	70,319	89,927	G	Total Expenditure	70,502	63,879	55,882	196,023	168,962	230,902
1,822	1,104	294	3,557	966	1,311	3	Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2]	10,960	13,172	14,311	40,677	53,471	61,086
23,327	21,057	22,576	71,782	71,285	91,238	4	Other Income	6,431	15,410	1,625	22,706	5,567	5,813
5,935	7,686	1,936	14,736	6,695	6,992	5	Profit before Interest & Exceptional Items [3 + 4]	17,391	28,582	15,936	63,383	59,038	66,899
17,392	13,371	20,640	57,046	64,590	84,246	6	Interest & Finance charges	4,430	5,974	748	11,091	2,926	3,181
0	0	0	0	0	0	7	Profit after Interest but before Exceptional Items [5 - 6]	12,961	22,608	15,188	52,292	56,112	63,718
17,392	13,371	20,640	57,046	64,590	84,246	8	Exceptional Items [+] Income / [-] Expense	0	0	0	0	0	0
1,736	2,351	3,680	6,941	9,596	10,636	9	Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8]	12,961	22,608	15,188	52,292	56,112	63,718
15,656	11,020	16,960	50,105	54,994	73,610	10	Tax expense	(460)	(490)	1,150	480	4,050	2,680
0	0	0	0	0	0	11	Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 - 10]	13,421	23,098	14,038	51,812	52,062	61,038
15,656	11,020	16,960	50,105	54,994	73,610	12	Extraordinary items [net of tax expense]	0	0	0	0	0	0
(735)	(752)	(759)	(1,934)	(1,791)	(2,510)	13	Net Profit [+] / Loss [-] for the period [11 - 12]	13,421	23,098	14,038	51,812	52,062	61,038
14,921	10,268	16,201	48,171	53,203	71,100	14	Adjustments on consolidation [+] Income / [-] Expense	0	0	0	0	0	0
10,237	10,237	10,237	10,237	10,237	10,237	15	Net Profit [+] / Loss [-] for the period [13 + 14]	13,421	23,098	14,038	51,812	52,062	61,038
						16	Paid-up equity share capital [Face Value Rs. 5 / -]	10,237	10,237	10,237	10,237	10,237	10,237
						17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						198,754
7.29	5.01	7.91	23.53	25.98	34.73	18	Earnings Per Share [EPS] [For the period - not Annualised]:						
7.29	5.01	7.91	23.53	25.98	34.73	A	Basic and Diluted EPS before Extraordinary items [Rs.]	6.55	11.28	6.86	25.31	25.43	29.81
						B	Basic and Diluted EPS after Extraordinary items [Rs.]	6.55	11.28	6.86	25.31	25.43	29.81
51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	19	Public shareholding :						
25.21%	25.21%	25.21%	25.21%	25.21%	25.21%	-	Number of shares	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474
						-	Percentage of Shareholding	25.21%	25.21%	25.21%	25.21%	25.21%	25.21%
						20	Promoters and Promoter group Shareholding :						
Nil	Nil	Nil	Nil	Nil	Nil	A	Pledged / Encumbered :						
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	-	Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	-	Percentage of shares [as a % of the total shareholding of promoters and promoter group]	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
						-	Percentage of shares [as a % of the total share capital of the company]	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
153,138,046	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046	B	Non-encumbered :						
100%	100%	100%	100%	100%	100%	-	Number of Shares	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046
74.79%	74.79%	74.79%	74.79%	74.79%	74.79%	-	Percentage of shares [as a % of the total shareholding of promoters and promoter group]	100%	100.00%	100.00%	100%	100.00%	100%
						-	Percentage of shares [as a % of the total share capital of the company]	74.79%	74.79%	74.79%	74.79%	74.79%	74.79%

Notes :

- [1] The above results for the quarter / nine months period ended on December 31, 2011 were reviewed by the Audit Committee on February 6, 2012 and then approved by the Board of Directors at their meeting held on February 7, 2012.
- [2] During the quarter, the Company has acquired 100% shareholding of Biochem Pharmaceutical Industries Limited ["Biochem"], a Mumbai based pharmaceutical Company. Consequent upon acquisition, Biochem has become a wholly owned subsidiary Company.
- [3] The change in Investments during the quarter are as under :
ZEST Aviation Private Limited [Divestment] - Rs. 200 Lacs
Zydus BSV Pharma Private Limited [Additional Investment] - Rs. 260 Lacs
- [4] During the quarter, the Company has adopted Accounting Standard 30 "Financial Instrument : Recognition and Measurement" to the extent adoption does not conflict with existing mandatory accounting standards and other authoritative pronouncements, Company Law and other regulatory requirements. This adoption has resulted in change in accounting policy followed by the Company. Consequent to this, the Company's net profit after tax for the current quarter is higher by Rs. 3146 Lacs [Rs. 3079 Lacs on consolidated basis].
- [5] The above financial results include loss on account of foreign exchange fluctuations of Rs. 3028 Lacs [Rs. 3417 Lacs on consolidated basis] for the quarter and Rs. 9865 Lacs [Rs. 10868 Lacs on consolidated basis] for the nine months period ended December 31, 2011.
- [6] The status of investor complaints :
Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 17, pending at the end of the quarter - Nil.
- [7] The Company has one segment of activity viz., "Pharmaceuticals".

Ahmedabad, February 7, 2012

For Cadila Healthcare Limited,



Pankaj R. Patel

Chairman & Managing Director

Zydus Cadila Total Income up by 20% in Q3

Ahmedabad, February 7, 2012

For the third quarter ended 31st December 2011, Zydus Cadila registered a Total Income of Rs. 1401 crores up by 20% from Rs. 1170 crores in the corresponding period last year, on a consolidated basis. The Net Profit excluding the impact of foreign exchange fluctuations loss was up by 7% to Rs. 177 crores from Rs. 165 crores in the corresponding period last year.

During the quarter, the group's India formulations business grew by 18%. The group launched 15 new products, of which, 7 were the first in India. Strengthening its operations in the Indian pharma market, the group acquired the Mumbai based Biochem, one of India's top 40 pharma companies. Biochem is a strong player in the antibiotics, cardiovascular, anti-diabetic and oncological segments. Business of the JV companies posted a healthy growth of 58% during the quarter.

Riding high on the increased sales of its own products and that of the recently acquired Neshier, the group's subsidiary in the US posted a growth of 45%. The group also posted a growth of 44% in sales in Japan. The group filed 5 more ANDAs this quarter, taking the total to 141 ANDA filings. For the EU market, 9 new product dossiers were filed taking the cumulative to 132. The group received 8 new product approvals for the EU market taking the cumulative approvals to 82. During the quarter, 7 more products were supplied to Spain from India. The group now supplies 12 products to Spain. Additionally, the group filed 11 new product dossiers for the Brazilian market and 10 new product dossiers for the Mexican market, taking the cumulative to 79 and 14, respectively.

During the quarter, the group launched PegiHep, the first true biosimilar pegylated interferon alfa-2b in India. Used in the treatment of Hepatitis B & C, PegiHep is the fifth biosimilar product from the robust biologics pipeline developed at the Zydus Research Centre.
